Pfizer 2010 Annual Report Download - page 29

Financial Review
Pfizer Inc. and Subsidiary Companies
•Celebrex is a treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis and acute pain in adults. Celebrex
worldwide revenues were relatively flat in 2010, compared to 2009. In the U.S., revenues have been adversely affected by generic
competition. Celebrex is supported by continued educational and promotional efforts highlighting its efficacy and safety profile for
appropriate patients.
•Viagra remains the leading treatment for erectile dysfunction and one of the world’s most recognized pharmaceutical brands after more
than a decade. Viagra worldwide revenues increased 2% in 2010, compared to 2009. In the U.S., Viagra revenues increased 3% in
2010, compared to 2009. Internationally, Viagra revenues increased 1%, due to a favorable impact of foreign exchange in 2010
compared to 2009. Viagra began facing generic competition in Spain and Finland in December 2009.
•Xalabrands consists of Xalatan, a prostaglandin, the world’s leading branded agent to reduce elevated eye pressure in patients with
open-angle glaucoma or ocular hypertension, and Xalacom, a fixed combination prostaglandin (Xalatan) and beta blocker (timolol) that
is available outside the U.S. Xalatan/Xalacom worldwide revenues increased 1% in 2010, compared to 2009. The increase was due to
higher revenues in the U.S., partially offset by lower international revenues due to the launch of generic latanoprost in Japan in May
2010 and in Italy in July 2010. Additionally, foreign exchange had a favorable impact in 2010, compared to 2009. We expect to lose
exclusivity for Xalatan in the U.S. in March 2011 and for Xalatan and Xalacom in the majority of major European markets in July 2011.
We are pursuing a pediatric extension for Xalatan in the EU. If we are successful, the exclusivity period for both Xalatan and Xalacom in
the majority of major European markets will be extended by six months to January 2012.
•Effexor XR (extended release capsules), an antidepressant for treating adult patients with major depressive disorder, GAD, social
anxiety disorder and panic disorder, recorded worldwide revenues of $1.7 billion in 2010. Effexor XR faces generic competition outside
the U.S. and, it has faced generic competition in the U.S. since July 1, 2010. This generic competition had, in 2010, and will continue to
have a significant adverse impact on our revenues for Effexor XR.
•Norvasc, for treating hypertension, lost exclusivity in the U.S. in March 2007. Norvasc also has experienced patent expirations in other
major markets, including Canada in July 2009 and Japan in March 2008. Norvasc worldwide revenues decreased 24% in 2010,
compared to 2009.
•Prevnar/Prevenar (7-valent), our 7-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in infants
and young children, had worldwide revenues of $1.3 billion in 2010. Certain markets have transitioned from the use of Prevnar/
Prevenar (7-valent) to Prevnar/Prevenar 13 (see discussion above) resulting in lower revenues for Prevnar/Prevenar (7-valent). We
expect this trend to continue.
•Zyvox is the world’s best-selling branded agent for the treatment of certain serious Gram-positive pathogens, including Methicillin-
Resistant Staphylococcus-Aureus (MRSA). Zyvox worldwide revenues increased 3% in 2010, compared to 2009, primarily due to
growth in emerging markets and developed markets in Europe. In the U.S., revenues have been adversely affected by flat market
growth and increased generic and branded competition.
•Sutent is for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC), and gastrointestinal
stromal tumors (GIST) after disease progression on, or intolerance to, imatinib mesylate. Sutent worldwide revenues increased 11% in
2010, compared to 2009, primarily due to strong operational performance in international markets. We continue to drive total revenue
and prescription growth, supported by cost-effectiveness data and efficacy data in first-line mRCC––including two-year survival data,
which represent the first time that overall survival of two years has been seen in the treatment of advanced kidney cancer, as well as
through increasing access and healthcare coverage. As of December 31, 2010, Sutent was the best-selling medicine in the world for
the treatment of first-line mRCC.
On July 1, 2010 the FDA approved revised labeling for Sutent, which includes a boxed warning concerning hepatotoxicity and
related changes to the warnings and precautions section. In addition, as part of a risk mitigation and communication plan, the
revised label includes a Medication Guide that patients will receive when Sutent is dispensed.
Pfizer maintains a global safety database, monitoring all sponsored clinical trials and spontaneous adverse event reports. Hepatic
failure has been uncommonly observed in clinical trials (0.3%) and post-marketing experience, consistent with the very low rate of
hepatic failure observed in the clinical trials of Sutent used to support original registration in 2006. Over 91,000 patients worldwide
have been treated with Sutent.
The risk-benefit profile of Sutent in both mRCC and second-line GIST has been well established through large, randomized
clinical trials evaluating its safety and efficacy. Sutent remains an important treatment option for these two difficult-to-treat
cancers.
•Our Premarin family of products remains the leading therapy to help women address moderate-to-severe menopausal symptoms. It
had worldwide revenues of $1.0 billion in 2010.
•Geodon/Zeldox, an atypical antipsychotic, is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of
bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. Geodon
worldwide revenues increased 2% in 2010, compared to 2009, due in part to continued growth in the U.S. antipsychotic market and the
recent U.S. approval of Geodon for adjunctive bipolar maintenance therapy in adults.
•Detrol/Detrol LA, a muscarinic receptor antagonist, is the most prescribed branded medicine worldwide for overactive bladder. Detrol
LA is an extended-release formulation taken once a day. Detrol/Detrol LA worldwide revenues declined 12% in 2010, compared to
2009, primarily due to increased competition from other branded medicines.
2010 Financial Report 27